Trial · NCT05167734
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hemoglobin Concentrations | 1 month post-hospitalization | Hemoglobin is a protein that cares oxygen through the body |
| Secondary | Hemoglobin Concentrations | Hospital discharge (approximately 1 month), 3 months post-hospitalization | Hemoglobin is a protein that cares oxygen through the body |
| Secondary | Phlebotomy Practice-Blood Draws | Hospital discharge (approximately 1 month) | Number of times subjects have blood drawn |
| Secondary | Phlebotomy Practice-Volume | Hospital discharge (approximately 1 month) | Total volume of phlebotomy blood draws |
| Secondary | Patient-Reported Quality of Life Measured by EuroQol (EQ-5D) | Hospital discharge (approximately 1 month), 1 month post-hospitalization, 3 months post-hospitalization | The EuroQol (EQ-5D) is a 5-item questionnaire that assess health-related quality of life over five different dimensions of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Total score ranges from 0 to 100, with higher scores indicating improved health. |
| Secondary | Anemia-related Fatigue Measured by Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale | Hospital discharge (approximately 1 month), 1 month post-hospitalization, 3 months post-hospitalization | The Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale is a 13-item questionnaire used to measure the severity of fatigue and its impact on daily activities. Each question is rated on a 4-point scale where 0 represents "very much" fatigued and 4 represents "not at all" fatigued. Total scores range from 0 to 52 with lower scores indicating greater fatigue. |
| Secondary | 6 Minute Walk Distance | 1 and 3-months post-hospitalization | Distance walked in 6 minutes used to assess physical function after critical illness. |
| Secondary | Cognitive Function After Critical Illness Assessed Using Montreal Cognitive Assessment (MoCA-BLIND) | 1 and 3-months post-hospitalization | The Montreal Cognitive Assessment (MoCA-BLIND) score assesses cognitive impairment by a 30-item questionnaire that includes tests of orientation, attention, memory, language and visual-spatial skills. Possible scores range from 0 to 30, with higher scores indicating higher cognitive function. A final total score of 26 and above is considered normal. |
| Secondary | Mental Health - Anxiety and Depression Measured Using the Hosptial Anxiety and Depression Scale (HADS) | 1 and 3-months post-hospitalization | The Hospital Anxiety and Depression Scale (HADS) assesses a patient's anxiety and depression levels. Subject's answer 14 questions (7 for anxiety and 7 for depression). Each question is scored from 0-3. Total scores can range from 0 to 21 for either anxiety or depression, with higher scores indicating a presence of anxiety or depression. |
| Secondary | Mental Health - Post-Traumatic Distress Using Impact of Events Scale-Revised (IES-R) | 1 and 3-months post-hospitalization | The Impact of Events Scale-Revised (IES-R) is a self-reported questionnaire that measures the distress caused by traumatic events. Subjects respond to 22 questions using a 5-point scale ranging from 0 (not at all) to 4 (extremely). Total scores range from 0 to 88, with a higher score indicting the likely presence of post-traumatic stress disorder (PTSD). |
| Secondary | Number of Participants With Allogeneic Red Blood Cell Transfusions | 3-months post-hospitalization | Number (percentage) of patients transfused with allogeneic red blood cells |
| Secondary | Number of Transfused Units of Allogeneic Red Blood Cells | 3 months post hospitalization | Number of transfused units from hospital discharge through 3-months post-hospitalization |
| Secondary | Unplanned Hospital Readmissions | 3 months and 12-months post-hospitalization | Number of subjects to experience an unplanned hospital readmission |
| Secondary | Mortality | 3 months and 12-months post-hospitalization | Mortality from any cause |
| Secondary | Adverse Events Post-enrollment | Hospital discharge (approximately 1 month), 3-months post-hospitalization | Venous thromboembolism, bloodstream infection, myocardial infarction, stroke |
| Secondary | Accelerometry-measured Number of Steps Taken Per Day | 1 and 3-months post-hospitalization | Home-based activity monitor daily step counts (optional, exploratory study component) |
| Secondary | Accelerometry-measured Daily Maximum Step Cadence | 1 month and 3 month post hospitalization | Actigraphy evaluated daily Max Step Cadence - i.e., steps per minute (optional, exploratory study endpoint) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05167734/registered